The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer.

被引:4
作者
Eng T.Y. [1 ]
Luh J.Y. [1 ]
Thomas Jr. C.R. [1 ]
机构
[1] Department of Radiation Oncology, UTHSCSA/Cancer Therapy and Research Center, 7979 Wurzbach Road, San Antonio, 78229, TX
关键词
Prostate Cancer; Hormonal Therapy; Radiat Oncol Biol Phys; Localize Prostate Cancer; Radiation Therapy Oncology Group;
D O I
10.1007/s11934-005-0008-3
中图分类号
学科分类号
摘要
Technologic advances in radiation treatment planning and delivery have generated popular interest in the different radiation therapy techniques used in treating patients with localized prostate cancer. Throughout the past decade, high-energy (> 4 MV) linear accelerators have largely replaced Cobalt machines in external beam radiation therapy (EBRT) delivery. Conventional EBRT has been used to treat prostate cancer successfully since the 1950s. By switching to computed tomography-based planning, three-dimensional conformal radiation therapy provides better relative conformality of dose than does conventional EBRT. Intensity-modulated radiation therapy (IMRT) has further refined dose conformality by spreading the low-dose region to a larger volume. However, the potential long-term risks of larger volumes of normal tissues receiving low doses of radiation in IMRT are unknown. Particle-beam radiation therapy offers unique dose distributions and characteristics with higher relative biologic effect and linear energy transfer. Transperineal prostate brachytherapy offers the shortest treatment time with equivalent efficacy without significant risk of radiation exposure. The addition of hormonal therapy to radiation therapy has been shown to improve the outcome of radiation therapy.
引用
收藏
页码:194 / 209
页数:15
相关论文
共 337 条
  • [1] Jemal A(2005)Cancer statistics, 2005 Cancer J Clin 55 10 -30
  • [2] Murray T(1993)Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening JAMA 270 948 -954
  • [3] Ward E(1965)Linear accelerator supervoltage therapy. VII: carcinoma of the prostate Radiology 85 121 -129
  • [4] Catalona WJ(1995)Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center J Urol 153 1026 -1031
  • [5] Smith DS(1997)Stage T1 -2 prostate cancer with pretreatment prostate-specific antigen level 10 ng/ml: Radiation therapy or surgery Int J Radiat Oncol Biol Phys 318 723 -729
  • [6] Ratliff TL(1991)Outcome for lymph node dissection negative T1b, T2 (A2,B) prostate cancer treated with external beam radiation therapy in RTOG 77 -06 Int J Radiat Oncol Biol Phys 21 1099-1103
  • [7] Bagshaw MA(1998)Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77 -06, Phase III study for TIBN0M0 (A2) and T2N0M0 (B) prostate carcinoma Int J Radiat Oncol Biol Phys 40 769 -782
  • [8] Kaplan HS(1997)External beam radiotherapy versus radical prostatectomy for clinical stage T1 -2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores Ca J Sci Am 3 78 -87
  • [9] Sagerman RH(1997)Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate-specific antigen of 4–20 ng/mL Int J Radiat Oncol Biol Phys 37 1053 -1058
  • [10] Fowler JE(1998)Radiation therapy versus radical prostatectomy in the PSA era: a urologist’s view Semin Radiat Oncol 8 87 -94